Voyager Therapeutics (VYGR) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $208.9 million.
- Voyager Therapeutics' Cash & Current Investments fell 3950.37% to $208.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $208.9 million, marking a year-over-year decrease of 3950.37%. This contributed to the annual value of $266.7 million for FY2024, which is 1551.01% up from last year.
- As of Q3 2025, Voyager Therapeutics' Cash & Current Investments stood at $208.9 million, which was down 3950.37% from $215.6 million recorded in Q2 2025.
- Voyager Therapeutics' Cash & Current Investments' 5-year high stood at $399.6 million during Q1 2024, with a 5-year trough of $118.8 million in Q4 2022.
- Its 5-year average for Cash & Current Investments is $220.9 million, with a median of $215.6 million in 2025.
- Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 9426.07% in 2023, then tumbled by 4189.2% in 2025.
- Over the past 5 years, Voyager Therapeutics' Cash & Current Investments (Quarter) stood at $132.5 million in 2021, then decreased by 10.33% to $118.8 million in 2022, then surged by 94.26% to $230.9 million in 2023, then increased by 15.51% to $266.7 million in 2024, then dropped by 21.66% to $208.9 million in 2025.
- Its Cash & Current Investments stands at $208.9 million for Q3 2025, versus $215.6 million for Q2 2025 and $236.0 million for Q1 2025.